Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$5.01 USD
+0.02 (0.40%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $5.01 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
PBYI 5.01 +0.02(0.40%)
Will PBYI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBYI
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Other News for PBYI
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI Crosses Above Average Analyst Target
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.